IDL Diagnostics AB (publ) (STO:IDLDX)

Market Cap	112.65M -16.6%
Revenue (ttm)	54.54M -9.0%
Net Income	-8.42M
EPS	-0.04
Shares Out	230.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,901
Open	0.4850
Previous Close	0.4900
Day's Range	0.4720 - 0.4890
52-Week Range	0.2500 - 0.5800
Beta	0.86
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 25
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IDLDX

Financial Performance

In 2025, IDL Diagnostics AB's revenue was 53.11 million, a decrease of -7.54% compared to the previous year's 57.44 million. Losses were -12.15 million, 264.0% more than in 2024.